Dr. Omar Gonzalez presents his Integrative Medicine Clinic in Mexico
http://www.placidway.com/profile/705/ - Watch this Video as Dr.Omar Gonzalez, MD, specialist in Stem Cell Therapy, Integrative Medicine and Chronic Diseases, presents his new clinic located...

By: placidways

Follow this link:
Dr. Omar Gonzalez presents his Integrative Medicine Clinic in Mexico - Video

Recommendation and review posted by simmons

DUBLIN, June 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/v969qd/cell_separation) has announced the addition of the "Cell Separation Technologies Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

This report consists of the market analysis for the various technologies used in the cell separation market. Increasing cell therapy oriented research and development globally is driving the cell separation technologies market towards significant growth. The stakeholders for this report include providers and manufacturers of cell separation technology instruments.

The cell separation technologies market is segmented on the basis of technologies that are available in the market and application areas of cell separation technologies. The various technology segments covered in this report are gradient centrifugation and separation based on surface markers. Separation based on surface markers technology include two different techniques namely, magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS).

The application areas of cell separation technologies comprise stem cell research, immunology, neuroscience research and cancer research. Revenue forecast and market analysis for each segment has been given in this study for the period of 2011 to 2019 in terms of USD million in addition to the compound annual growth rate (CAGR %) for each segment of technology and application. The CAGR is provided for forecast period of 2013 to 2019 and 2012 have been considered as base in year for market size estimation.

Geographically, global cell separation technologies market has been segmented into four areas namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). This report also provides the present and future market estimation in terms of USD million for the period 2011 to 2019, in addition to compound annual growth rate (CAGR %) for each geographic area. Further to market size estimation, this report provides recommendations and highlights of the market that should be useful for current and new market players to grow and sustain in the global cell separation technologies market.

Market trends and dynamics such as restraints, opportunities and growth drivers that have impact on present and future position of this market are demonstrated in the market overview chapter of this study. In addition, the market overview chapter also consists of Porter's five forces analysis and market attractiveness by geography to give detailed analysis of the entire competitive status of the global cell separation technologies market.

Key information about the top market players operating in the global cell separation technologies market is given in the company profiles section of this report. Some of the key players profiled in this report include BD Bioscience, EMD Millipore, Mitenyi Biotec GmbH, and STEMCELL Technologies, Terumo BCT, pluriSelect GmbH, and Life Technologies (Thermo Fisher Scientific, Inc.).

Key Topics Covered:

Chapter 1 Introduction

Visit link:
Cell Separation Technologies Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Recommendation and review posted by simmons

PUBLIC RELEASE DATE:

9-Jun-2014

Contact: Kimberly Brown kbrown@snmmi.org 703-652-6773 Society of Nuclear Medicine

St. Louis, Mo. (June 9, 2014) Researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting revealed how a protein encourages the production of stem cells that regenerate damaged tissues of the heart following an acute attack (myocardial infarction). They further assert that it has a better chance of working if provided early in treatment. This was confirmed by molecular imaging, which captured patients' improved heart health after therapy.

If given after a heart attack, granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow stem cells that turn down the collateral damage of cell death that occurs after acute myocardial infarction. Other research has shown G-CSF having a beneficial impact on left ventricle ejection fraction, a measurement of how powerfully the heart is pumping oxygenated blood back into the aorta and the rest of the body with each beat. The objective of this study was to find out how beneficial the stem cellstimulating therapy would be if administered early during standard treatment. Early prescription of G-CSF happens to strengthen its effect immediately and after follow up.

"Previous studies have shown that giving G-CSF to unselected heart attack patients failed to satisfactorily improve their condition, but G-CSF may potentially be beneficial if given earlier than 37 hours following myocardial infarction and coronary intervention," remarked Takuji Toyama, MD, the study's principal researcher from the division of cardiology at Gunma Prefectural Cardiovascular Center in Maebashi, Japan. "This study shows that the first intravenous drip infusion of G-CSF during treatment just after hospitalization was able to rescue our patients. I am confident that with additional data from a forthcoming clinical trial, this protocol can be adopted as a standard of practice."

For this study, 40 consecutive patients with acute myocardial infarction were given either G-CSF therapy or saline intravenously for a total of five days beginning during a selected minimally invasive treatment, otherwise known as percutaneous cardiac intervention. Results of one year's worth of SPECT stress tests nailed how earlier start of G-CSF therapy in heart attack patients improves blood flow, access to essential energy and overall cardiac function.

Coronary heart disease caused one out of every six fatalities in the U.S. in 2010, according to 2014 statistics from the American Heart Association. An estimated 620,000 Americans suffered a first heart attack, and 295,000 had a recurrent episode. Collectively, heart attacks occur about once every 34 seconds. Coronary events cause about 379,559 deaths each year.

###

Scientific Paper 239: Takuji Toyama, Hiroshi Hoshizaki, Hakuken Kan, Ren Kawaguchi, Hitoshi Adachi, Shigeru Ohsima, Division of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan; Masahiko Kurabayashi, Department of Cardiovascular Medicine, Gunma University School of Medicine, Maebashi, Japan, "Is the granulocyte colony-stimulating factor therapy in the earliest phase effective to rescue patients with acute myocardial infarction?" SNMMI's 61th Annual Meeting, June 7, 2014, St. Louis, Missouri.

Originally posted here:
Stem cell-stimulating therapy saves heart attack patients

Recommendation and review posted by simmons

SOUTH BEND, Ind.--- In the 1970's, researchers discovered that a newborn's umbilical cord blood contained special stem cells that could help fight certain diseases.

More than 30 years later doctors are still experimenting and learning more about the use of cord blood.

Amanda Canale doesn't take time with her daughter and niece for granted.

She's just happy to feel good.

"I've been in the hospital, and I've been sick my whole life," said Amanda.

Amanda was born with a rare blood disorder that required daily shots.

"Basically, I have no white blood cells. I have no immune system at all," said Amanda

At 23 she developed Leukemia and was given two weeks to live.

She desperately needed a Bone Marrow Transplant, but family members weren't matches.

Her doctor suggested an Umbilical Cord Blood Transplant.

View post:
Umbilical cord blood helps to save lives

Recommendation and review posted by Bethany Smith

LOUISVILLE, Ky. -- Robert Waddell says he's glad the stem cells that healed him came from "a guy who was 50 years old" and not a human embryo.

As a Catholic, Waddell opposes the destruction of embryos and didn't want to rely on embryonic stem cells to cure his kidney disease. But he avoided this moral dilemma by getting bone marrow stem cells from a friend who donated a kidney as part of a University of Louisville study.

"It has nothing to do with embryonic stem cells," said Waddell, a 47-year-old father of four. "That made it a lot easier."

Recent strides in stem-cell research show adult stem cells to be ever-more-promising, many scientists say, quelling the controversy steeped in faith and science that has long surrounded embryonic stem cells.

In fact, University of Louisville researcher Scott Whittemore said the debate is almost moot.

"Realistically, (many scientists don't use) the types of stem cells that are so problematic anymore," he said, adding that adult stem cells can now be reprogrammed to behave like embryonic stem cells. "The field has moved so fast."

In addition to these genetically reprogrammed adult cells - known as induced pluripotent stem cells or iPS cells - scientists are on the cusp of being able to turn one type of cell into another in the body without using stem cells at all. They shared some of the latest research last week at the annual International Society for Stem Cell Research in Vancouver.

"IPS cells overcame the main ethical issues," namely the use of embryos some Americans consider sacred human life, said Brett Spear, a professor of microbiology, immunology and molecular genetics at the University of Kentucky who uses iPS cells to model liver disease.

But other scientists argue that embryonic stem cell research remains important.

Dr. George Daley, director of the stem cell transplant program at Boston Children's Hospital and past president of the research society, said embryonic cells are a tool in the search for cures.

The rest is here:
Stem-cell advances may quell ethics debate

Recommendation and review posted by Bethany Smith

Author Rating:

Ten minutes into trying Stem Cellular Instant Eye Lift Products by Juice Beauty I knew I was hooked for life. These products are made for the rushing around "tired as all hell mommy who needs a quick pick me up. Your eyes will truly be transformed in 10 amazing minutes. The process is merely two steps (activator fluid meets algae face mask) and the result is reduced fine lines, wrinkles and puffiness. What you are left with is younger looking brighter eyes.

Each box contains six pure marine algae face masks and six Activator Fluid capsules. It is safe for all skin types and an authentic organic product. Vitamin C promotes brightness while white tea, cucumber and arnica extract reduces puffiness. Algae and Aloe hydrate, fruit stem cells promote firmness and camomile and hyaluronic acid encourage skin texture. This unique formula is created without use of parabens, petroleum, pesticides and other harmful additives and none of the products are tested on animals.

I was asking as you probably are how this can be accomplished so quickly. To start, pour the Activator fluid on the face masks and soak them. Once saturated, apply the mask under the eye for 10 minutes. Its that easy and you truly see results! You can choose to follow this treatment with Juice Beauty's Stem Cellular Eye Treatment. The initial treatment retails for around $75.00 while the supplemental treatments in the product line retail for $45-65. The whole line is completely worth the expense! I was amazed!

For more information or to purchase products please visit http://www.juicebeauty.com. You can also find them on Facebook at http://www.facebook.com/juicebeauty, and at Amazon.com.

Visit link:
Juice Beauty Stem Celluar Line

Recommendation and review posted by Bethany Smith

2014 Vanderbilt GSC 3MT Finalist: Dikshya Bastakoty - Cardiovascular cell therapy
2014 Vanderbilt GSC 3MT Finalist: Dikshya Bastakoty - Cardiovascular cell therapy: teaching stem cells to fix the broken heart.

By: VanderbiltGSC

Continue reading here:
2014 Vanderbilt GSC 3MT Finalist: Dikshya Bastakoty - Cardiovascular cell therapy - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

10-Jun-2014

Contact: Lucy Handford lucy.handford@monash.edu Monash University

Researchers have discovered that mutations in one of the brain's key genes could be responsible for impaired mental function in children born with an intellectual disability.

The research, published today in the journal, Human Molecular Genetics, proves that the gene, TUBB5, is essential for a healthy functioning brain.

It's estimated that intellectual disability affects up to four per cent of people worldwide, and two per cent of all Australians. One of the ways in which intellectual disability occurs is through genetic mutations, which cause problems with normal fetal brain development.

During fetal brain development, TUBB5 is essential for the proper placement and wiring of new neurons. When the gene is mutated, the brain, which sends and receives messages to the rest of the body, is impaired.

Lead researcher, Dr Julian Heng, from the Australian Regenerative Medicine Institute (ARMI) at Monash University, said genetic mutations to TUBB5 could be responsible for a range of intellectual disabilities. It could also affect the development of basic motor skills such as walking.

"TUBB5 works like a type of scaffolding inside neurons, enabling them to shape their connections to other neurons, so it's essential for healthy brain development. If the scaffolding is faulty, in this case of TUBB5 mutates, it can have serious consequences," Dr Heng said.

These new findings build on the team's collaborative work with researchers in Austria, which led to the discovery of TUBB5 mutations in human brain disorders in 2012. By looking at just three unrelated patients with microcephaly, a rare brain disease in children, the team found striking similarities each had a mutation to TUBB5. The team also provided the first evidence that the TUBB5 mutations were responsible for each patient's disorder.

See original here:
Gene mutation discovery could explain brain disorders in children

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

11-Jun-2014

Contact: Siobhan Gallagher siobhan.gallagher@tufts.edu 617-636-6586 Tufts University, Health Sciences Campus

BOSTON (June 11, 2014) Researchers from Tufts have gained new insight into a protein associated with bipolar disorder. The study, published in the June 3 issue of Science Signaling, reveals that calcium channels in resting neurons activate the breakdown of Sp4, which belongs to a class of proteins called transcription factors that regulate gene expression.

This study, led by Grace Gill, identifies a molecular mechanism regulating Sp4 activity. Her previous research had determined that reduced levels of Sp4 in the brain are associated with bipolar disorder. Her work overall suggests that misregulation of Sp4 may contribute to the development of bipolar disorder.

"Understanding how transcription factors like Sp4 are regulated may provide us with ways to change neuronal gene expression to treat symptoms of mental illness, including bipolar disorder," said Gill, Ph.D., an associate professor in the department of developmental, molecular & chemical biology at Tufts University School of Medicine and member of the neuroscience; genetics; and cell, molecular and developmental biology program faculties at the Sackler School of Graduate Biomedical Sciences at Tufts.

The main goal of the study was to determine whether a specific type of calcium channel store-operated calcium channels drive the breakdown of Sp4 protein. Along the way, however, the research team also discovered that signaling by these calcium channels is most active in the so-called "off" or "resting" phase.

"The calcium-signaling regulation of Sp4 during the resting phase was unexpected and suggests two things: resting neurons are more active than we had thought and calcium signaling influences gene expression in both active and resting neurons," Gill said.

"We tend to think about cells being "on" or "off," but the reality of the biology is far more complex. Cells are always busy," she continued.

In neurons cells that can be stimulated by electrical signals transcription factors are regulated by calcium entry that is initiated when the cell depolarizes. Depolarization occurs when the overall voltage of the cell is increased. This is the "on" or "active" state for the cell. In contrast, when the cell's voltage is decreased, hyperpolarization occurs. This is called the "off" or "resting" phase for the cell.

Follow this link:
Researchers identify regulation process of protein linked to bipolar disorder

Recommendation and review posted by Bethany Smith

May 2014 Breaking News Mixing Human DNA with Animal DNA Last days final hour news prophecy
May 2014 Breaking News Mixing Human DNA with Animal DNA - Last Days End Times News Prophecy Update - Genetic Engineering.

By: nilay

Read more from the original source:
May 2014 Breaking News Mixing Human DNA with Animal DNA Last days final hour news prophecy - Video

Recommendation and review posted by Bethany Smith

Welcome to GM in Australia, a The Conversation series looking at the facts, ethics, regulations and research into genetically modified (GM) crops. In this first instalment, Peter Langridge describes two GM techniques: selective breeding and genetic engineering.

GENETIC modification (GM) sounds very laboratory-based people in white coats inserting and deleting genes but the vast majority of GM work was completed in the field through selective breeding.

Early Middle Eastern farmers collected grain from natural grasslands, but they needed to time their harvest very carefully. If they were too early the grain wouldnt store well, and if they were too late the grain would spread over the ground making collection difficult.

At some stage, one of these early farmers must have noticed that some heads remained fixed on their stems even after the grain was fully dry. He obviously didnt understand this at the time, but these were plants with a mutation in the genes controlling seed dispersal.

Farmers began preferentially choosing plants with this useful mutation and planting them, perhaps the first case of breeding and selecting for a novel trait.

Gregor Mendel.

Wikimedia, CC BY

Systematic breeding really began in the early 1900s when scientists rediscovered Silesian monk Gregor Mendels groundbreaking work on genetic inheritance in peas.

Breeding involves utilising genetic variation to produce new combinations of genes and gene variants. A breeder will cross two different lines and then select offspring that have improved performance.

More:
GM: from the field to the lab

Recommendation and review posted by Bethany Smith

Take a hot new method that's opened up a new era of genetic engineering, apply it to the wonder stem cells that in 2012 won their discoverer a Nobel prize, and you might just have a tool to cure HIV infection.

That's the hope of researchers led by Yuet Kan of the University of California, San Francisco and they have proved the basic principle, altering the genome of induced pluripotent stem cells (iPSCs) to give them a rare natural mutation that allows some people to resist HIV.

Kan's work relies on "genome editing" snipping out a particular DNA sequence and replacing it with another. It's much more precise than traditional forms of genetic engineering, in which sequences are added to the genome at random locations.

To alter the stem cells, Kan's team turned to the CRISPR-Cas9 system, a super-efficient method of genome editing based on an ancient bacterial "immune system". In bacteria, the system takes fragments of DNA from invading viruses and splices them into the cell's own DNA, where they act like "wanted" posters, allowing the viruses to be recognised and attacked in future.

About 1 per cent of people of European descent are resistant to HIV, because they carry two copies of a mutation in the gene for a protein called CCR5. The virus must lock onto this protein before it can invade white blood cells, and the mutations prevent it from doing so.

Using a bone marrow transplant from a naturally HIV-resistant person, Timothy Ray Brown was famously "cured" of HIV infection. Kan's goal is to achieve the same result without the need to find compatible HIV-resistant bone marrow donors who are in vanishingly short supply.

It's fairly easy to make iPSCs from a person's cells, which then have the potential to grow into any type of cell in the body. So if iPSCs could be given two copies of the protective mutation, it should be possible to make personalised versions of the therapy that cleared HIV from Brown's body. Kan's team has now shown that CRISPR-Cas9 can efficiently make the necessary genome edit. As expected, white blood cells grown from these altered stem cells were resistant to HIV upon testing.

"It's a really fantastic application of the tool," says Philip Gregory, chief scientific officer with Sangamo BioSciences of Richmond, California. However, he warns that there is a long way to go before it can be turned into a practical therapy.

Kan has not yet grown the iPSCs into the specific type of white blood cells called CD4+ T cells that are ravaged by HIV. What he instead plans to do is turn the iPSCs into blood-forming stem cells, which when transplanted into the body would give rise to all of the cell types found in the blood. "One of the problems is converting iPSCs into a type of cell that is transplantable," says Kan. "It is a big hurdle."

Regulators will also need to be convinced that cells that have been subjected to extensive genetic manipulation both to create the iPSCs, and to give them the protective mutation are safe.

Follow this link:
Gene editing tool can write HIV out of the picture

Recommendation and review posted by Bethany Smith

Clewiston, FL -

Numbers released Wednesday by the US Department of Agriculture show production of oranges in Florida is projected to be down 22 percent this month compared to the same time last year.

Citrus experts expect the numbers will continue to fall.

The main reason for the decline comes from an insect that is as common as the mosquito in Florida, which is spreading an incurable disease called Citrus Greening.

Oranges are a $9-billion industry in the state and to help protect it, everything is being considered including genetic engineering.

Southern Gardens Citrus in Clewiston is spearheading some genetic research. Its facility processes 25,000 oranges per minute, with the capacity of making 600,000 gallons of juice per day.

The groves feeding the facility are in visible distress. There are rows of stumps left behind from infected trees, where 800,000 have been infected so far.

President of Southern Gardens Citrus, Ricke Kress, has been looking for a cure for nine years. He's been with the company since 2005, which is the same year the disease was found in his groves.

"I had been here about a month." Kress Said, adding, "if we take out every infected tree we're basically not going to have any trees left.

Citrus Greening is spread through bacteria called Asian Citrus Psyllid, which essentially cuts off nutritional flow inside of the tree.

Read the original here:
Florida orange production down, projections show

Recommendation and review posted by Bethany Smith

WASHINGTON - A rare set of genetic mutations found in fewer than one percent of the population may cut the risk of heart disease by 40 percent, researchers said Wednesday.

The findings in the New England Journal of Medicine show how certain flaws in a gene called APOC3 work to reduce a certain type of fat found in blood, known as triglycerides.

About one in 150 people carry one of these four genetic mutations, said the findings based on a study of the DNA of nearly 4,000 people of European and African ancestry.

Normal levels of triglycerides are generally less than 150 milligrams per deciliter (mg/dL). Among those with any of the four APOC3 mutations, triglyceride levels were around 85 mg/dL.

"Based on our findings, we predict that lowering triglycerides specifically through inhibition of APOC3 would have a beneficial effect by lowering disease risk," said senior co-author Alex Reiner, a research professor of epidemiology at the University of Washington's School of Public Health.

Drugs already exist that can lower triglycerides -- which like cholesterol are a type of lipid in the blood -- but these have not been proven to lower the risk of heart disease, perhaps because they don't lower the lipids enough, researchers said.

Continued here:
Gene flaws that reduce fat in blood may protect against heart disease

Recommendation and review posted by Bethany Smith

2013 08 07 Q A 193 Fasting on Watermelon, Cholesterol, Genetics Experiences
Web site: http://www.drmorsesherbalhealthclub.com Official YouTube channel: https://www.youtube.com/user/robertmorsend.

By: Aru Shizuka

Follow this link:
2013 08 07 Q&A 193 Fasting on Watermelon, Cholesterol, Genetics & Experiences - Video

Recommendation and review posted by Bethany Smith

EX-GEN - CLOSER (Extreme Genetics 0.2) - 3D Vision Recordings // Out 15/07/2k14
3DVEP010 EX-GEN EXTREME GENETICS 0.2 Tracklist: 01 CLOSER 02 PROMETHEUS with ABSOLUM 03 RETREAT The EX-GEN strike back !!! The scientists were hard at work i...

By: EX-GEN NANUK

The rest is here:
EX-GEN - CLOSER (Extreme Genetics 0.2) - 3D Vision Recordings // Out 15/07/2k14 - Video

Recommendation and review posted by Bethany Smith

Advanced Genetics - Minecraft Mod
Minecraft Mod - Playlist: http://castcrafter.de/MinecraftMods Advanced Genetics: http://castcrafter.de/AdvancedGenetics Abonnieren: http://bit.ly/1qTeka2 Twitter: http://bit.ly/ZcZ...

By: CastCrafter

Read this article:
Advanced Genetics - Minecraft Mod - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

10-Jun-2014

Contact: Ronald Rogers rrogers@myriad.com 801-584-3065 Myriad Genetics, Inc.

SALT LAKE CITY, Utah, June 10, 2014 Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that Vectra DA data will be featured in eight posters at the 2014 European League Against Rheumatism (EULAR) Annual Meeting, June 11-14, 2014, in Paris, France. Vectra DA is a quantitative, objective multi-biomarker test to measure disease activity in patients with rheumatoid arthritis (RA). The Vectra DA test offers insight into the biological processes that drive disease activity to help rheumatologists manage RA and improve patient care.

At EULAR, data will be presented by researchers from the Swedish Farmacotherapy (SWEFOT) clinical trial that demonstrate the clinical utility of Vectra DA in assessing the risk of future joint damage at multiple points in time. Additionally, SWEFOT data indicate that changes in Vectra DA scores were associated with favorable response to both non-biologic and biologic therapies. Further, the data demonstrate that Vectra DA may have the potential to serve as an inclusion criterion for assessing patients who are candidates for clinical trials in rheumatoid arthritis.

"The breadth of data presented at EULAR is representative of the clinical utility of Vectra DA in the overall management of RA," said Oscar Segurado, chief medical officer at Crescendo Bioscience. "Vectra DA provides physicians with important, actionable insight to better assess risk of radiographic progression as well as manage therapy decisions in their patients with a precise and standardized tool. The EULAR data also point out the opportunity to identify more patients that may be eligible to participate in clinical trials."

The data to be presented at this EULAR meeting will build on a recently published study in the journal Annals of Rheumatic Diseases that demonstrated that Vectra DA scores at the start of the SWEFOT clinical study predicted radiographic progression of joint damage over the following year. The new data from the SWEFOT study being presented at EULAR demonstrate that Vectra DA scores at 3 months and 12 months also were predictive of subsequent radiographic progression over the following 2 years. Additionally, patients in the SWEFOT study who did not respond to 3 months of initial methotrexate therapy were randomized to receive either non-biological DMARD triple therapy or anti-TNF (infliximab) therapy. Patients with a high Vectra DA score at baseline that remained high following therapy were at a high risk for radiographic progression. By contrast, risk for progression was significantly lower among patients with a high Vectra DA score at baseline, but lower Vectra DA score following treatment. At all measured time points, low Vectra DA scores were associated with low risk for subsequent radiographic progression.

"These are clinically relevant findings for rheumatologists taking care of patients with RA," said Ronald F. van Vollenhoven, M.D., Ph.D, Department of Medicine, Karolinska Institute in Stockholm, Sweden. "These data show that Vectra DA may help identify those patients at higher and lower risks for radiographic progression while receiving antirheumatic therapy."

Poster Tour Presentations

Title: Using the multi-biomarker disease activity score as a complementary inclusion criterion for clinical trials in rheumatoid arthritis may enhance recruitment. Presenter: Ronald van Vollenhoven Date: Presentation: June 13, 2014 12:00 PM, Room 251 Poster: June 14, 2014; 10:15 AM, Poster Area D, Level 4 Key Finding: In this analysis of the SWEFOT study, Vectra DA was found to be potentially useful as an inclusion criterion in clinical trials. Recruitment for clinical trials in patients with active RA may be enhanced by including patients with a Vectra DA score > 44 in addition to the conventional approach of only using patients with a CRP > 10 mg/L. This enhancement was achieved with a comparable response to treatment and subsequent radiographic progression. In this study the number of eligible DMARD nave patients increased by 24 percent and the number of eligible MTX Non-responder patients increased by 47 percent.

Visit link:
Crescendo Bioscience to present multiple studies at 2014 EULAR Meeting

Recommendation and review posted by Bethany Smith

Genetics start-up 23andMe said on Friday it is one step closer to resuming sales of its full-fledged health product, with the U.S. Food and Drug Administration accepting its first health report for review.

The home genetics company said in a blog post that the FDA will begin evaluating the company's submission for a 510(k) application, a regulatory process that applies to most medical devices sold in the United States.

Kathy Hibbs, 23andMe's chief legal and regulatory officer, said in the blog post that the submission focused on one single inherited condition, called Bloom Syndrome.

"Once cleared, it will help 23andMe, and the FDA, establish the parameters for future submissions,'' Hibbs writes.

Read More 3 promising tech darlings that fell flat

In November of 2013, the Google-backed firm stopped selling its $99 DNA test until it obtained marketing authorization from the FDA. 23andMe had previously said in its marketing materials that it could deliver insights about people's genetic predispositions toward "254 diseases and conditions.''

But in a public warning letter last November, addressed to 23andMe's chief executive Anne Wojcicki, the FDA expressed concerns about the "public health consequences of inaccurate results'' from 23andMe's genetic test kit.

Bradley Merrill Thompson, a product regulatory attorney with Epstein Becker & Green, said this was an important "milestone'' for 23andMe. The process may still take time, he added, as FDA will likely have further questions or requests for information.

Read More China's genomics success shows big data challenges

"But this does reveal 23andMe's strategyand that's to go through the process with the FDA.''

Read this article:
23andMe on path to FDA approval

Recommendation and review posted by Bethany Smith

Jazzmin, C5 SCI, on RT600 at Project Walk Atlanta -Spinal Cord Injury Recovery
a C5-C7 SCI complete injury, ASIA A No rehab place in Indiana would let her use this machine because they said she wouldn #39;t be able to, she said "WATCH ME". ...

By: Project Walk Atlanta-Paralysis Recovery Center, SCI MS

See the article here:
Jazzmin, C5 SCI, on RT600 at Project Walk Atlanta -Spinal Cord Injury Recovery - Video

Recommendation and review posted by sam

Rotimi Adesanya | credits: File copy

Treatment

Treatment for sickle cell anaemia (SS) is usually aimed at avoiding crises, relieving symptoms and preventing complications. A person with sickle cell anaemia will need to make regular visits to the hospital to check the red blood cell count and monitor his/her health.

Treatment may include antibiotics, vitamins, daily folic acid, blood transfusions, pain-relieving medicines, supplemental oxygen, fluid therapy and other medications; and possibly surgery to correct vision problems or to remove a damaged spleen.

Self/home management: It is advisable that a sickle cell patient drinks plenty of water, eat balanced diets that contain all classes of food in the right proportions, including fresh fruits and vegetables; take regular non strenuous exercises, keep warm in cold weather, and cool in hot weather.

Antibiotics: Children with sickle cell anaemia may begin taking the antibiotic penicillin when they are about two months of age and continue taking it until they are five years old.

Anti-malarials: Children with sickle cell anaemia should be given anti-malarial prophylaxis from time to time in order to prevent crises.

Pain-relieving medications: To relieve pain during a sickle crisis, over-the-counter pain relievers and application of heat to the affected area should be deployed. Stronger pain medication can also be prescribed by the doctor.

Dietary supplements: Ciklavite, Trevor, Jobelyn and many more are some dietary supplements (adjuvants) that play supportive role in the management of sickle cell disease.

Hydroxyurea: When taken daily, hydroxyurea reduces the frequency of painful crises and may reduce the need for blood transfusions. It may be an option for adults with severe case of the disease. It is only administered under strict medical supervision.

Read the rest here:
Managing sickle cell disorder (2)

Recommendation and review posted by Bethany Smith

By Jerome Burne

Published: 18:34 EST, 16 June 2014 | Updated: 18:34 EST, 16 June 2014

Fred had rare and aggressive cancer in his adrenal glands (illustrated) and lived for nearly three years thanks to highly sophisticated gene test

Fred Barker was diagnosed with a rare but aggressive form of cancer in his adrenal glands just over three years ago. It came as a dreadful shock to the 44-year-old.

Most patients with this sort of tumour have less than six months left.

But Fred lived for nearly three years thanks to a highly sophisticated gene test that's set to revolutionise the way cancers are treated.

This looks for certain genes in tumours - if the cancer has these genes, the patient can then be given drugs that are known to target them specifically.

More than 80per cent of doctors change the treatment plan for those in their care following genetic tumour testing, according to research presented at the American Society of Clinical Oncology earlier this month. In another study, patients with ovarian cancer who had the test had a 36per cent lower risk of death from their illness compared with those who didn't.

A similar test recently became available on the NHS, and nearly 1,000 patients with cancer that has spread have had it. But few UK oncologists are aware this testing is now available - and fewer patients know enough to be able to ask for it.

Fred was lucky - he was living in Perth, Australia, when he became ill. He had already undergone surgery and chemotherapy but scans had shown that his cancer was still growing and had spread to his spine, ribs and a shoulder blade.

Original post:
Gene test that transforms your chances of beating cancer

Recommendation and review posted by Bethany Smith

Movie Fun Run ICGEB 2014

By: International Centre for Genetic Engineering and Biotechnology

The rest is here:
Movie Fun Run ICGEB 2014 - Video

Recommendation and review posted by Bethany Smith

EDMONTON - If you, like many consumers, shop for food in the middle aisles of the grocery store where processed foods fill the shelves, you are likely buying products that contain genetically modified ingredients.

Yet you probably arent aware which products contain which modified ingredients, since in Canada there are no requirements that GM foods be labelled. Nor are you likely aware why and how the ingredients have been modified.

And, no doubt, youre unsure if it matters.

Genetic modification has been a polarizing issue since genetically modified seeds were first approved and planted in Canada in the mid-1990s. But with consumers increasingly keen to know where their food comes from, the topic of whats in their food is also attracting renewed attention.

I think people are genuinely interested in their food, says Ellen Goddard, a University of Alberta economist who studies consumer response to new technologies. Something about the GM debate has intrigued them. They want to know more about how their food is produced.

She adds: Consumers will almost always say they want more information.

Genetically modified organisms, popularly known as GMOs, are created when the genetic code is altered to either express a desirable trait or supress or remove an undesirable one. At its heart, genetic engineering is a short cut that speeds up the work of selective breeding, work that has been going on for centuries, but at a slower pace indeed, nearly every food crop grown today has been modified through this older process. Much of the opposition to genetic engineering of foods is focused on the practice of inserting genetic code from one organism into another, which cannot happen under natural circumstances.

Its this idea of mutant food forms that first spawned the Frankenfood nickname back in the 1990s.

The reality is only a few actual crops are genetically modified, but because they are widely used, they appear in many food products. The only GM crops grown in Canada are corn, soy, canola and sugar beets. But those crops are used in animal feed and as ingredients in thousands of processed foods on our grocery shelves. According to the Grocery Manufacturers Association, up to 75 per cent of conventional processed foods in a typical supermarket contain ingredients dervied from GMOs.

Go here to see the original:
Fields of gold ... or plains of ruin? The debate over genetically modified seeds in Alberta rages on

Recommendation and review posted by Bethany Smith

Attack of the B-TEAM | Super Modded Survival | #8 | Advanced Genetics!
8: We are still working on the base, just a quick update on whats going on and then some fun with advanced genetics also featuring +Beardlesskid https://w...

By: DadVsMinecraft

Link:
Attack of the B-TEAM | Super Modded Survival | #8 | Advanced Genetics! - Video

Recommendation and review posted by Bethany Smith